News|Articles|April 2, 2026

Generare Raises €20 Million to Scale AI-Driven Molecular Discovery

Listen

0:00 / 0:00

Key Takeaways

A €20M Series A co-led by Alven and Daphni will expand evolution-derived small-molecule datasets to support pharma and agrochemical discovery workflows.
AI model performance is limited less by compute than by training data novelty, with drug discovery repeatedly recycling constrained chemical space.
Microbial genomes encode vast unexplored biosynthetic diversity, with ~97% of molecular potential uncharacterized and thus inaccessible to conventional libraries.
High-throughput genome mining plus expression and phenotypic/structural characterization generates new compounds and new datapoints, creating a compounding data flywheel for discovery.
Scaling targets include >2000 molecules by 2027 and >10,000 longer term, aiming to reposition natural products as a systematic, industrialized input to modern R&D.

The funding will support expansion of evolution-derived molecule datasets, enabling discovery of novel bioactive compounds and improving AI model performance in drug development.

Generare, a Paris-based techbio company, announced a €20 million (US$23 million) Series A financing round on April 2, 2026 intended to scale its evolution-based molecular discovery platform. The investment highlights growing investor interest in data-driven approaches to expanding chemical space for drug development. The round was co-led by Alven and Daphni, with participation from existing investors.¹

The funding will support expansion of Generare’s proprietary dataset of novel small molecules, scaling its discovery capacity tenfold by 2027 to meet increasing demand from pharmaceutical and agrochemical companies. The company aims to build one of the largest commercially available libraries of evolution-derived compounds, positioning itself at the intersection of synthetic biology, genomics, and artificial intelligence (AI).

Why is novel molecular data becoming a bottleneck in drug discovery?

Drug discovery has historically operated within a limited chemical space, constrained not by computational capability but by the availability of high-quality molecular data. While AI has accelerated drug design and screening, its effectiveness depends heavily on the diversity and novelty of underlying datasets.²

“Drug discovery has a data problem. The entire field trains its models on the same recycled chemistry and expects different outcomes. The bottleneck is not algorithms, it is the absence of genuinely novel, high-quality molecular data.”

Generare targets this limitation by decoding previously inaccessible chemistry embedded in microbial genomes. These genomes represent billions of years of evolutionary experimentation, with an estimated 97% of their encoded molecular diversity remaining unexplored.¹

Using proprietary high-throughput cloning and sequencing technologies, the company screens microbial DNA to identify gene sequences likely to produce bioactive compounds. These sequences are then expressed and characterized for structure, biological activity, and drug potential, generating new data points that continuously expand the platform’s dataset.

“Drug discovery has a data problem. The entire field trains its models on the same recycled chemistry and expects different outcomes,” said Guillaume Vandenesch, CEO and co-founder of Generare, in a company press release.¹ “The bottleneck is not algorithms, it is the absence of genuinely novel, high-quality molecular data.”

What differentiates the company’s platform in a competitive techbio landscape?

By uncovering evolution-derived molecules with unique structures and mechanisms, the company aims to provide new starting points for therapeutic development that are not accessible through traditional synthetic libraries.

In 2025, Generare identified more than 200 previously uncharacterized molecules, exceeding the combined output of other players in the field. These molecules are now being evaluated by research laboratories for potential applications in treating life-threatening diseases.

Vincent Libis, PhD, Generare’s co-founder and chief scientific officer, emphasized the role of natural products as a foundation for innovation. “Nature has been the number one source of innovative modes of action for drugs, and we’ve only scratched the surface of its potential,” he said in the release.¹

What does funding like this mean for the future of AI-driven drug discovery?

The investment reflects broader industry recognition that access to novel biological data is critical for unlocking the full potential of AI in drug discovery. While computational models continue to evolve, their ability to generate meaningful insights depends on exposure to diverse and biologically relevant chemical structures.³

Generare plans to scale its dataset to more than 2000 molecules by 2027, with longer-term ambitions to exceed 10,000 compounds. The funding will also support expansion of its multidisciplinary team, which currently includes experts in computational biology, chemistry, and synthetic biology.

Investors highlighted the company’s potential to redefine how natural products are integrated into modern drug discovery. By systematically unlocking previously inaccessible molecular diversity, Generare aims to shift the industry from designing within known chemical boundaries to exploring new regions of chemical space.¹

References

Generare. Generare raises €20M after generating more novel high quality molecules in 2025 than the rest of the field combined. Published April 2, 2026. Accessed April 2, 2026.
Blanco-González A, Cabezón A, Seco-González A, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals (Basel). 2023;16(6):891. doi: 10.3390/ph16060891
Alucozai M, Fondrie W, Sperry M. From data to drugs: the role of artificial intelligence in drug discovery. Published Jan. 9, 2025. Accessed April 2. 2026. https://wyss.harvard.edu/news/from-data-to-drugs-the-role-of-artificial-intelligence-in-drug-discovery/

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.